OYAGEN
OyaGen, Inc., a biotechnology company, engages in discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. Its platform technology encompasses on study of editing enzymes to affect various functions, including antiviral, cancer, immunoglobulin gene rearrangements, inflammation, ion channel function, LDL reduction, neuro-cognitive functions, and red blood cell expression in fetal liver. OyaGen, Inc. was founded in 2003 and is based in Rochester, New York.
OYAGEN
Social Links:
Industry:
Biotechnology Genetics Health Care
Founded:
2003-01-01
Address:
Rochester, New York, United States
Country:
United States
Website Url:
http://www.oyageninc.com
Total Employee:
11+
Status:
Active
Contact:
5852756007
Total Funding:
5.92 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Wordpress Plugins
Similar Organizations
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Investors List
Managing Director at the RockCreek Group
Managing Director at the RockCreek Group investment in Grant - OyaGen
Trillium Group
Trillium Group investment in Series A - OyaGen
Official Site Inspections
http://www.oyageninc.com Semrush global rank: 5.87 M Semrush visits lastest month: 1.41 K
- Host name: 25.233.71.198.host.secureserver.net
- IP address: 198.71.233.25
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "OyaGen"
OyaGen – HIV drug discovery towards a cure
OyaGen’s extensive experience with drug discovery from assay development to screening and mechanistic studies are also available as fee-for-service to academia and industry partners …See details»
Company Infrastructure – OyaGen
The Company occupies a 3,200 sq. ft. state-of-the-art laboratory within the Rochester BioVenture Center in Rochester NY. A broad range of advanced instrumentation, controlled environments …See details»
OyaGen - Crunchbase Company Profile & Funding
OyaGen, Inc., a biotechnology company, engages in discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit RNA editing and DNA …See details»
OyaGen - Wikipedia
OyaGen is a Rochester, New York-based startup company that is focused on developing treatments for HIV. The company was founded in 2003 by Harold Smith, a professor of biochemistry and biophysics at the University of Rochester. OyaGen was founded on research conducted by Smith and Hui Zang, an HIV researcher at Thomas Jefferson University. See details»
Investors – OyaGen
OyaGen will soon complete IND-enabling studies and engage the FDA in preIND discussions for its a patent-protected, first-in-class antagonist of the HIV-1 Vif protein that protects the …See details»
OYAGEN INC. - LinkedIn
OYAGEN INC. | 204 followers on LinkedIn. OYAGEN is a biotechnology company formed on September 5, 2003, for the purpose of discovering, developing, and commercializing novel …See details»
OyaGen, Inc - VentureRadar
"OyaGen is a Rochester, New York -based startup company that is focused on developing treatments for HIV. The company was founded in 2003 by Dr. Harold Smith, a professor of …See details»
OYAGEN Company Profile - Office Locations, Competitors, …
OYAGEN has 5 employees at their 1 location and $5.92 m in total funding,. See insights on OYAGEN including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
OyaGen Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for OyaGen. Use the PitchBook Platform to explore the full profile.See details»
OyaGen, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Www.oyageninc.com. Holding Company | 2003 | New York, United States | 10-50 | www.oyageninc.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational …See details»
Oyagen, Inc. Details - govtribe.com
Mar 18, 2009 Summary Posted 4/25/24, 2:53 PM Oyagen, Inc. Oyagen Division - doing business as Oyagen Inc., is a biotechnology company formed in 2003 for the purpose of discovering, …See details»
OyaGen - Overview, News & Similar companies | ZoomInfo.com
Apr 19, 2021 Oyagen, Inc. Publishes Study On Its OYA1 As A "Highly Effective" Experimental Drug Candidate For Treating Infections By The Ebola Virus ROCHESTER, N.Y., Jan. 7, 2021 …See details»
OyaGen, Inc first-in-class drug lead for HIV and Ebola - LinkedIn
Jun 6, 2019 There is also a Wikipedia page on OyaGen, Inc and two medical animations describing the HIV therapeutic and cure approaches (searchable in YouTube under …See details»
OyaGen, Inc. announces a new publication for its COVID …
Sep 18, 2023 For more information on OyaGen, Inc., please visit the company's website at www.oyageninc.com or call OyaGen, Inc. at (585) 697-4351. SOURCE OyaGen, Inc.See details»
Executive Summary - oyageninc.com
Executive Summary Overview OyaGen has its origins in the science of gene editing enzymes that affect the genetic readout of cells and viruses, through the academic work of Dr. Harold C. …See details»
Ryan Bennett - Chief Scientific Officer and Lab Director - LinkedIn
Nov 5, 2016 Chief Scientific Officer and Lab Director at OyaGen, Inc. · Both my graduate and professional research experience has been focused on A3G enabling me to develop novel …See details»
OyaGen, Inc. Announces a Compound in Development with Broad …
ROCHESTER, N.Y., March 11, 2020 /PRNewswire/ -- OyaGen, Inc. announced today new unpublished results from collaborative research with the National Institute of Allergy and …See details»
People - OyaGen
Strategic Development Advisory Board. Dr. Richard C. Ogden RORR Inc. Dr. David Ho (Senior Consultant to the Scientific Advisory Board) CEO Aaron Diamond AIDS Research Center & …See details»
Oyagen, Inc. Publishes Study On Its OYA1 As A "Highly Effective ...
ROCHESTER, N.Y., Jan. 7, 2021 /PRNewswire/ -- OyaGen, Inc. announced today publication in VIRUSES, a peer reviewed journal, of studies carried out by OyaGen in collaboration with …See details»
Executive Summary – OyaGen
Executive Summary Overview. OyaGen has its origins in the science of gene editing enzymes that affect the genetic readout of cells and viruses, through the academic work of Dr. Harold C. …See details»